Document is current
Any future updates will be listed below
-
Authors
Decaix, Théodore https://orcid.org/0009-0002-0142-0210
Kemache, Kenza
Gay, Pierre
Ketz, Flora
Laprévote, Olivier
Pautas, Éric
- License Information
-
More Information
Article History
Received: 31 January 2024
Accepted: 26 April 2024
First Online: 22 May 2024
Declarations
:
: Study methodology corresponds to studies not involving human subjects (MR – 004). The study was conducted in accordance with the Declaration of Helsinki and the database was declared to the French National Commission on Computing and Liberty (CNIL) of the Assistance Publique – Hôpitaux de Paris (APHP) for this study (n° 20,230,403,102,132).
: The requirement for informed consent by individual patients was waived by the CNIL affiliated with the Assistance Publique - Hôpitaux de Paris (AP-HP) given the retrospective nature of the study. Patients that expressed in the medical chart an opposition to the use of their clinical data were excluded from the study.
: E. Pautas has received honoraria for participating in expert meetings on dabigatran (from Boehringer Ingelheim), rivaroxaban (from Bayer Healthcare AG), apixaban (Bristol Myers Squibb-Pfizer), and warfarin (Merck).
